Lytix Biopharma ASA · OSL:LYTIX

Lytix Biopharma ASA — Investor Presentation (February 2018)

38 slides from Lytix Biopharma ASA's investor presentation, February 2018

  1. Slide 1: Investor Presentation February 2018

    INVESTOR PRESENTATION February 2018 Turning cold tumors hot 1

  2. Slide 2: Agenda

    1 INTRODUCTION 2 LTX-315 – COMPREHENSIVE SCIENTIFIC FOUNDATION 3 LTX-315 – CLINICAL DATA IN MONOTHERAPY AND IN COMBINATION 4 HIGHLIGHTS AND SUPPORTING DATA 2

  3. Slide 3: Today's presenters and company in brief

    T O D AY ’ S P R E S E N T E R S C O M PA N Y I N B R I E F Edwin Klumper CEO, M.D., PhD, MBA Lytix Biopharma is a clinical-stage pharmaceutical company,  Life science entrepreneur with a strong combination of developing novel immunotherapies to fight cancer scientific and business background The c

  4. Slide 4: Strong growth in immuno-oncology, however low response rates remain a challenge

    STRONG GROWTH IN IMMUNO-ONCOLOGY, HOWEVER LOW RESPONSE RATES REMAIN A CHALLENGE CHECKPOINT INHIBITORS, GLOBAL REVENUE RESPONSE RATES TO CHECKPOINT INHIBITORS IN MONOTHERAPY Responders Non-responders USD, billion 6,4 MALIGNANT MELANOMA 2,6 1,4 TRIPLE NEGATIVE 1,0 0,7 BREAST CANCER 0,4 2011 2012 2013

  5. Slide 5: Oncolytic peptide LTX-315 opens up for a personal cancer immune response

    ONCOLYTIC PEPTIDE LTX-315 OPENS UP FOR A PERSONAL CANCER IMMUNE RESPONSE RAPID AND DIRECT LYSIS OF CANCER CELLS Time: 0 min 5 min 10 min 20 min Recognition of the patients personal antigens (the unique barcode of the cancer cells) Strong stimulus of the innate immune system  Targeting and disintegr

  6. Slide 6: LTX-315 turns cold tumors hot and primes the tumor

    LTX-315 TURNS COLD TUMORS HOT AND PRIMES THE TUMOR 90% SUCCESS RATE TURNING COLD TUMORS HOT PRE-TREATMENT LTX-315 INJECTED IMMUNE STAINING NANO- STRING 15 out of 17 evaluable patients with increased T cell infiltration in LTX-315 monotherapy 6 Immune staining: CD3 staining in breast carcinoma patien

  7. Slide 7: Efficient immunotherapy requires both a priming phase and an effector phase

    EFFICIENT IMMUNOTHERAPY REQUIRES BOTH A PRIMING PHASE AND AN EFFECTOR PHASE PRIMING PHASE EFFECTOR PHASE  Generation of tumor specific T cells  Destruction of the cancer cells by the T cells  Intratumoral therapy with LTX-315 ideal  Systemic therapy ideal — Local stimulation and tumor antigens r

  8. Slide 8: LTX-315 is the ultimate personalized cancer therapy

    LTX-315 IS THE ULTIMATE PERSONALIZED CANCER THERAPY  EFFICACY  SAFETY  DRUG PRODUCT  Comprehensive immunogenic cell  Transient side effect profile  Short half-life of ~20min death by targeting mitochondria  Low risk of neutralizing antibodies  Low manufacturing cost  Effective release of th

  9. Slide 9: Leading experts engaged to develop LTX-315 as cornerstone drug

    LEADING EXPERTS ARE ENGAGED TO DEVELOP LTX-315 AS A CORNERSTONE DRUG IN IMMUNONCOLOGY CO-OPERATION WITH LEADING UNIVERSITIES AND KOLs ENSURES HIGH VISIBILITY AND INSIGHT INTO LATEST DEVELOPMENTS SELECTION OF LEADING RESEARCH SITES SELECTION OF LEADING KEY OPINION LEADERS Prof. Mikael Pittet, PhD Ass

  10. Slide 10: Drug development pipeline

    DRUG DEVELOPMENT PIPELINE Indication Program Research Preclinical Phase I/II Phase II Phase III All solid tumors LTX-315 Malignant melanoma LTX-315 in combo with (MM) ipilimumab Triple Negative Breast LTX-315 in combo with Cancer (TNBC) pembrolizumab LTX-315 in combo with TNBC or MM checkpoint inhib

  11. Slide 11: Market overview of current and planned indications

    MARKET OVERVIEW OF CURRENT AND PLANNED INDICATIONS MALIGNANT MELANOMA TRIPLE NEGATIVE BREAST CANCER SOFT TISSUE SARCOMA HEAD AND NECK METASTATIC PATIENTS METASTATIC PATIENTS METASTATIC PATIENTS METASTATIC PATIENTS Incidence, USA: 30,000 Incidence, USA: 39,000 Incidence, USA: 1,900-3,700 Incidence, U

  12. Slide 12: The immuno-oncology landscape is evolving and LTX-315 can have a central role

    THE IMMUNO-ONCOLOGY LANDSCAPE IS EVOLVING AND LTX- 315 CAN HAVE A CENTRAL ROLE IN SOLID TUMORS IMMUNE CHECKPOINT INHIBITORS IMMUNE STIMULANTS/ACTIVATORS VACCINES AND CELL THERAPIES ONCOLYTIC THERAPIES  Antibodies  Antibodies  Peptides  Oncolytic Peptides - aPD-1/PD-L1/CTLA-4 - OX-40,4-1BB, ICOS

  13. Slide 13: Agenda: LTX-315 scientific foundation

    1 INTRODUCTION 2 LTX-315 – COMPREHENSIVE SCIENTIFIC FOUNDATION 3 LTX-315 – CLINICAL DATA IN MONOTHERAPY AND IN COMBINATION 4 HIGHLIGHTS AND SUPPORTING DATA 13

  14. Slide 14: Comprehensive scientific foundation of LTX-315 documenting its potential

    COMPREHENSIVE SCIENTIFIC FOUNDATION OF LTX-315 DOCUMENTING ITS POTENTIAL IN IMMUNO-ONCOLOGY 1 Unique mode of action disintegrating mitochondria results in effective tumor specific immune response 2 Triggers a unique immunogenic cell death with release of danger signals and tumor antigens 3 Induces s

  15. Slide 15: LTX-315's unique mode of action results in effective release and reshape

    1 LTX-315`S UNIQUE MODE OF ACTION RESULTS IN EFFECTIVE "RELEASE AND RESHAPE" IN THE TUMOR MICROENVIRONMENT 15 Zhou, Cell Death & Disease 2016. Zhou, Oncotarget 2015. Forveille, Cell Cycle 2015. Eike, Oncotarget, 2015. Camilio, OncoImmunology 2014, Camilio, Cancer Immunol Immunother, 2014

  16. Slide 16: LTX-315 targets mitochondria and releases danger signals and tumor antigens

    2 LTX-315 TARGETS MITOCHONDRIA AND RELEASE DANGER SIGNALS AND TUMOR ANTIGENES UNIQUE TARGETING OF MITOCHONDRIA LTX-315 IMMUNOGENIC CELL DEATH (ICD)  Unique targeting of the mitochondria results in an effective  Releasing potent immune stimulants and inducing all release of both danger signals and

  17. Slide 17: LTX-315 demonstrates systemic immune response, complete regression with tumor specific memory

    3 LTX-315 DEMONSTRATES SYSTEMIC IMMUNE RESPONSE – COMPLETE REGRESSION WITH TUMOR SPECIFIC MEMORY TUMOR 2 TUMOR 3 RECHALLENGE NON-INJECTED NON-INJECTED DECEASED DECEASED Control Rapid tumor growth in control group 1st 2nd LTX-315 injected mice showed tumor LTX-315 specific memory 3rd Days after tumor

  18. Slide 18: LTX-315 demonstrates synergy with checkpoint inhibitors and chemotherapy

    5 LTX-315 DEMONSTRATES SYNERGY WITH CHECKPOINT INHIBITORS AND CHEMOTHERAPY WITH IMMUNE CHECKPOINT INHIBITORS ANTI CTLA-4 ANTI PD-1 400 400 300 300 Tumor size (mm2) Tumor size (mm2) Control Iso Ctrl + PBS LTX-315 αPD1 + PBS 200 200 aCTLA-4 Iso Ctrl + LTX- 315 100 aCTLA4 + LTX-315 100 αPD1 + LTX-315 0

  19. Slide 19: Strong international collaborations demonstrating LTX-315 anti-tumor effects

    6 STRONG INTERNATIONAL COLLABORATIONS DEMONSTRATING LTX-315 ANTI-TUMOR EFFECTS LTX-315’s ability to reprogram tumors Prof M. Pittet LTX-315’s ability to release neo-antigens Prof R. Schreiber LTX-315 and involvement of Toll-like receptors (TLR) Dr. J. Oppenheim LTX-315’s ability to circumvent resist

  20. Slide 20: Agenda: clinical data

    1 INTRODUCTION 2 LTX-315 – COMPREHENSIVE SCIENTIFIC FOUNDATION 3 LTX-315 – CLINICAL DATA IN MONOTHERAPY AND IN COMBINATION 4 HIGHLIGHTS AND SUPPORTING DATA 20

  21. Slide 21: Overview of LTX-315 clinical program

    OVERVIEW OF LTX-315 CLINICAL PROGRAM 2010–2012 2013–2018 Type Phase I Phase I/II – Part A Phase I/II – Part B (Ongoing) Monotherapy arm Indication All solid tumors Combo with pembrolizumab All solid tumors All solid tumors Breast cancer (TN) Combo with ipilimumab Malignant melanoma Treatment Monothe

  22. Slide 22: Clinical data for LTX-315 in monotherapy and combo confirms its potential

    CLINICAL DATA FOR LTX-315 IN MONOTHERAPY AND COMBO WITH CHECKPOINT INHIBITORS CONFIRMS ITS POTENTIAL 1 Safety confirmed in +70 patients in monotherapy and in combination with checkpoint inhibitors (ongoing) 2 LTX-315 turns ~90% of tumors hot and ensures infiltration of CD8+ T cells into the injected

  23. Slide 23: Key safety outcomes

    1 SAFETY CONFIRMED IN +70 PATIENTS IN MONOTHERAPY AND IN COMBINATION WITH CHECKPOINT INHIBITORS PHASE I PHASE I PHASE I/II - ONGOING  Once weekly for 6 weeks to a single  Daily injections Days 1-3 week 1; once  3 arms: Monotherapy or in combination tumor weekly weeks 2-6 with pembrolizumab or ipi

  24. Slide 24: LTX-315 turns 90% of tumors hot and ensures infiltration of CD8+ T cells

    2 LTX-315 TURNS 90% OF TUMORS HOT AND ENSURES INFILTRATION OF CD8+ T CELLS TO KILL THE CANCER CELL MONOTHERAPY: 15 OUT OF 17 EVALUABLE PATIENTS COMBO WITH PEMBROLIZUMAB: 4 OUT OF 5 EVALUABLE PATIENTS MYO-EPITHELIOMA BREAST CARCINOMA BREAST CARCINOMA BREAST CARCINOMA BASELINE BASELINE CD8 CD8 CD8 CD8

  25. Slide 25: LTX-315 expands T cells in circulation and in the tumor

    MONOTHERAPY 2 LTX-315 EXPANDS T CELLS IN CIRCULATION AND IN THE TUMOR INCREASED TUMOR SPECIFIC T CELL PRESENT IN BLOOD INCREASED TUMOR SPECIFIC T CELL PRESENT IN TUMOR Number of expanded T cell clones detected in circulation T cell clone distribution (% found in both circulation and in the tumor) Ne

  26. Slide 26: LTX-315 turns tumors hot by upregulating key genes involved in tumor regression

    MONOTHERAPY 3 LTX-315 TURNS TUMORS HOT COMPREHENSIVELY BY UPREGULATING KEY GENES INVOLVED IN TUMOR REGRESSION INCREASED KEY GENE EXPRESSION POST INJECTION IMMUNOSIGN® 21 SCORE PRE INJECTION POST INJECTION Key genes Patients 26 Of the 15 patients in monotherapy where tumors turned from cold to hot, s

  27. Slide 27: Monotherapy stable disease in evaluable patients with large tumor burden

    MONOTHERAPY 4 STABLE DISEASE IN 8 OF 15 EVALUABLE PATIENTS WITH LARGE TUMOR BURDEN AND EXTENSIVE PRETREATMENT Sarcoma Melanoma Melanoma Sarcoma Sarcoma CANCER PATIENTS (TYPES) Melanoma Advanced disease patients Melanoma  10 patients in stage IV Breast cancer  5 patients in stage III Vaginal SCC 

  28. Slide 28: Anti-tumor effects documented in non-injected tumor

    PATIENT CASE REPORT 5 ANTI-TUMOR EFFECTS DOCUMENTED IN NON-INJECTED TUMOR PATIENT BACKGROUND LARGE NON-INJECTED LESION PRE/POST INJECTIONS  38 year female, adrenocortical cancer, diagnosed in year 2000. BASELINE Metastasis to lung, liver, peritoneum, bone.  Multiple prior treatments: surgery, chem

  29. Slide 29: Durable complete response in stage IV melanoma patient with pembrolizumab

    PATIENT CASE REPORT 6 DURABLE COMPLETE RESPONSE IN STAGE IV MELANOMA PATIENT WITH PEMBROLIZUMAB POST LTX-315 TREATMENT July May September Extensive metastasis Started LTX-315 injections Progression with new lesions 2009 Chemotherapy until 34 injections in two Started pembrolizumab October 2012 tumor

  30. Slide 30: Emerging data shows promising response rate in triple negative breast cancer

    COMBINATION WITH PEMBROLIZUMAB 7 EMERGING DATA SHOWS PROMISING RESPONSE RATE IN TRIPLE NEGATIVE BREAST CANCER PEMBRO MONOTHERAPY LTX-315 AND PEMBROLIZUMAB IN COMBINATION Pembrolizumab Phase II Triple negative breast cancer READOUT BY WEEK 7-8 response rates (Cohort A, pretreated patients) STABLE PAR

  31. Slide 31: Summary of clinical outcomes to date

    SUMMARY OF CLINICAL OUTCOMES TO DATE MONOTHERAPY MONOTHERAPY/COMBINATIONS PHASE I PHASE I/II - ONGOING LTX-315 - Tumor effect (CT scan) LTX-315 + pembrolizumab (Triple negative breast cancer) STABLE PARTIAL DISEASE RESPONSE 8 7 2 3 7 LTX-315 - Immune response injected tumors COLD TO HOT COLD TO HOT

  32. Slide 32: Development program with multiple readouts producing strong newsflow

    DEVELOPMENT PROGRAM WITH MULTIPLE READOUTS PRODUCING STRONG NEWSFLOW 2017 2018 2019 2020 H1 H2 H1 H2 H1 H2 H1 H2 Monotherapy Mixed tumors: LTX-315 Phase I/II Sarcoma: Phase II Adoptive T cell transfer Head and neck: Phase II Neoadjuvant setting Combination Malignant melanoma: Phase I/II LTX-315 + an

  33. Slide 33: Phase II combination trial with LTX-315 to optimize priming of the immune system

    8 PHASE II COMBINATION TRIAL WITH LTX-315 TO OPTIMIZE THE PRIMING OF THE IMMUNE SYSTEM FOR BETTER OUTCOMES TRIAL DESIGN IS BEING FINALIZED WITH EXPERT PANEL ADDRESSING THE LATEST INSIGHTS BACKGROUND TRIAL DESIGN Multidrug combinations are required to improve patient outcomes Testing different local

  34. Slide 34: Exploratory Phase II trials in sarcoma and head & neck cancers

    8 EXPLORATORY PHASE II TRIALS IN SARCOMA AND HEAD&NECK CANCERS ARE UNIQUE OPPORTUNITIES  Sarcomas are typically cold tumors also known as “immune deserts”  High unmet medical need  LTX-315 to generate specific tumor infiltrating lymphocytes (T cells) and boost SARCOMA adoptive T cell therapy  En

  35. Slide 35: Agenda: highlights and supporting data

    1 INTRODUCTION 2 LTX-315 – COMPREHENSIVE SCIENTIFIC FOUNDATION 3 LTX-315 – CLINICAL DATA IN MONOTHERAPY AND IN COMBINATION 4 HIGHLIGHTS AND SUPPORTING DATA 35

  36. Slide 36: Lytix Biopharma investment highlights

    LYTIX BIOPHARMA INVESTMENT HIGHLIGHTS UNIQUE PRODUCT  Ideal drug for personalizing immunotherapy in combination with other drugs  Turning “cold tumors hot” with a broad and deep immunogenic activation 1  Promising clinical data in patients refractory to other available treatment  Strong patent p

  37. Slide 37: Strong patent portfolio with protection until 2032

    STRONG PATENT PORTFOLIO WITH PROTECTION UNTIL 2032 Product Description EU US JP Other1 Chemically modified peptides Methods-of-use claims Granted, expires 2019 3 granted, expires 2022 Granted expires 2019 AU, NO, CA (incl. LTX-315) 2 granted, expires 2029 and Adaptive immunity Methods-of-use claims

  38. Slide 38: Increased levels of tumor infiltrating lymphocytes are associated with improved survival

    INCREASED LEVELS OF TUMOR INFILTRATING LYMPHOCYTES (TILs) ARE ASSOCIATED WITH IMPROVED SURVIVAL BASELINE TILs HAVE BEEN SHOWN TO BE A PREDICTIVE FACTOR FOR SURVIVAL IN TRIPLE NEGATIVE BREAST CANCER IN COMBINATION WITH CHECKPOINT INHIBITOR IN COMBINATION WITH CHEMOTHERAPY 14 12,6 12 MEDIAN OVERALL SU

Lytix Biopharma — Investor Presentation (February 2018) on 6ix